Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults

Erin Gatza; Pavan Reddy; Sung Won Choi

doi:10.1016/j.bbmt.2020.01.004

Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults

Biol Blood Marrow Transplant. 2020 May;26(5):e101-e112. doi: 10.1016/j.bbmt.2020.01.004. Epub 2020 Jan 11.

Authors

Erin Gatza¹, Pavan Reddy², Sung Won Choi³

Affiliations

¹ Department of Pediatrics, Division of Hematology-Oncology, University of Michigan, Ann Arbor, Michigan.
² Department of Internal Medicine, Division of Hematology-Oncology, Blood & Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan.
³ Department of Pediatrics, Division of Hematology-Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: sungchoi@med.umich.edu.

Abstract

Acute graft-versus-host disease (GVHD) continues to be a major cause of morbidity and mortality after allogeneic hematopoietic cell transplant (HCT) in pediatric patients (ie, children and adolescent and young adults) and limits broader application of the therapy. Pediatric HCT patients have faced major obstacles to access clinical trials that test new agents for GVHD prevention and treatment. According to a recent search, only 6 clinical trials of interventions for prevention or treatment of acute GVHD were conducted specifically in pediatric patients in the United States over the past decade, with 8 internationally. In this review, we summarize the studies that were performed and specifically enrolled and reported on pediatric patients after allogeneic HCT and provide a listing of studies currently under way.

Keywords: Acute GVHD; Clinical trials; HCT; Pediatrics.

Publication types

Review

MeSH terms

Acute Disease
Adolescent
Child
Graft vs Host Disease* / prevention & control
Hematopoietic Stem Cell Transplantation*
Humans
Transplantation, Homologous
Young Adult

Abstract

Publication types

MeSH terms

Grants and funding